Using Platelet-Rich Plasma PRP to Treat Female Fertility Problems Including Ovarian and Uterine Conditions

What this Trial Is About

Female fertility can be affected by several factors including ovarian function, fallopian tube health, the uterine environment, and mental state, with the ovaries and endometrium playing key roles. Common reproductive diseases impacting fertility include ovarian dysfunction, poor ovarian response, intrauterine adhesion, recurrent implantation failure, and thin endometrium. These conditions currently lack effective treatments, and platelet-rich plasma PRP shows promise, prompting further research into its effects and mechanisms. This study evaluates the use of platelet-rich plasma injections delivered via transvaginal or laparoscopic methods for ovarian diseases such as premature ovarian insufficiency and poor ovarian response. For uterine diseases including intrauterine adhesion, thin endometrium, and repeated implantation failure, PRP is administered through intrauterine perfusion or injections under the endometrium. The study focuses on monitoring the safety of PRP treatment up to three months post-enrollment. Participants are female patients aged 18 to 50 years diagnosed with one of the specified reproductive diseases. Their progress will be tracked through assessments of adverse and serious adverse events from enrollment through the three-month treatment period. Researchers will evaluate the safety of PRP injections and collect data to better understand its potential therapeutic effects in reproductive medicine.

Application of Platelet-rich Plasma (PRP) in Reproductive Medicine